Evidence map›Paper›PMID 38876270›Full record

ArticleBone2024

Sclerostin antibody enhances implant osseointegration in bone with Col1a1 mutation.

Hsiao H Sung, Hanna H Kwon, Chris Stephan, Skylar M Reynolds, Zongrui Dai, Peter M Van der Kraan, Michelle S Caird, Esmeralda N Blaney Davidson, Kenneth M Kozloff

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hsiao H SungOrthopaedic Research Laboratories, Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, MI, USA; Department of Oral and Maxillofacial Surgery, University of Michigan, Ann Arbor, MI, USA; Experimental Rheumatology, Department of Rheumatology, Radboud Medical Centre, Nijmegen, the Netherlands.
Hanna H KwonDepartment of Oral and Maxillofacial Surgery, University of Michigan, Ann Arbor, MI, USA.
Chris StephanOrthopaedic Research Laboratories, Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, MI, USA.
Skylar M ReynoldsOrthopaedic Research Laboratories, Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, MI, USA.
Zongrui DaiDepartment of Biostatistics, University of Michigan, Ann Arbor, MI, USA.
Peter M Van der KraanExperimental Rheumatology, Department of Rheumatology, Radboud Medical Centre, Nijmegen, the Netherlands.
Michelle S CairdOrthopaedic Research Laboratories, Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, MI, USA.
Esmeralda N Blaney DavidsonExperimental Rheumatology, Department of Rheumatology, Radboud Medical Centre, Nijmegen, the Netherlands.
Kenneth M KozloffOrthopaedic Research Laboratories, Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, MI, USA. Electronic address: kenkoz@umich.edu.

Funding

Structure, Composition, & Histology Core - Core BP30AR069620 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KARL J JEPSEN · 2016 to 2026
$8.4M
Biomarking the Sclerostin Antibody Effects on Osseointegration in an Osteogenesis Imperfecta ModelK08DE030116 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SUNG HSIEH, HSIAO HSIN · 2021 to 2024
$600k
In Vivo Micro-Computed Tomography Imaging SystemS10OD017979 · OD · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KOZLOFF, KENNETH M · 2015 to 2015
$393k
Biologic signatures for sclerostin antibody responsiveness in human and murine models of osteogenesis imperfectaR21AR075197 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KOZLOFF, KENNETH M · 2019 to 2020
$378k
NIAMS NIH HHS P30 AR069620NIAMS NIH HHS R21 AR075197NIDCR NIH HHS K08 DE030116NIH HHS S10 OD017979
6 · The paper itself

Abstract

We evaluated the potential of sclerostin antibody (SclAb) therapy to enhance osseointegration of dental and orthopaedic implants in a mouse model (Brtl/+) mimicking moderate to severe Osteogenesis Imperfecta (OI). To address the challenges in achieving stable implant integration in compromised bone conditions, our aim was to determine the effectiveness of sclerostin antibody (SclAb) at improving bone-to-implant contact and implant fixation strength. Utilizing a combination of micro-computed tomography, mechanical push-in testing, immunohistochemistry, and Western blot analysis, we observed that SclAb treatment significantly enhances bone volume fraction (BV/TV) and bone-implant contact (BIC) in Brtl/+ mice, suggesting a normalization of bone structure toward WT levels. Despite variations in implant survival rates between the maxilla and tibia, SclAb treatment consistently improved implant stability and resistance to mechanical forces, highlighting its potential to overcome the inherent challenges of OI in dental and orthopaedic implant integration. These results suggest that SclAb could be a valuable therapeutic approach for enhancing implant success in compromised bone conditions.

Indexed as

Adaptor Proteins, Signal TransducingAntibodiesCollagen Type IMutationOsseointegrationAnimalsBone and BonesDental ImplantsIntercellular Signaling Peptides and ProteinsMiceTibiaX-Ray MicrotomographyAdaptor Proteins, Signal TransducingAntibodiesCollagen Type IDental ImplantsIntercellular Signaling Peptides and ProteinsSost protein, mouseAlveolar boneMaxillaOsteogenesis imperfectaSclerostinTibia

Identifiers

PMID38876270
PMCPMC11243590

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.